KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) EBIAT (2016 - 2025)

Historic EBIAT for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $124.8 million.

  • BeOne Medicines' EBIAT rose 20287.68% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 10796.67%. This contributed to the annual value of -$644.8 million for FY2024, which is 2687.08% up from last year.
  • Per BeOne Medicines' latest filing, its EBIAT stood at $124.8 million for Q3 2025, which was up 20287.68% from $94.3 million recorded in Q2 2025.
  • BeOne Medicines' 5-year EBIAT high stood at $215.4 million for Q3 2023, and its period low was -$590.7 million during Q4 2021.
  • Over the past 5 years, BeOne Medicines' median EBIAT value was -$348.4 million (recorded in 2023), while the average stood at -$250.1 million.
  • In the last 5 years, BeOne Medicines' EBIAT crashed by 75448.23% in 2022 and then surged by 20287.68% in 2025.
  • BeOne Medicines' EBIAT (Quarter) stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then increased by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 182.2% to $124.8 million in 2025.
  • Its EBIAT stands at $124.8 million for Q3 2025, versus $94.3 million for Q2 2025 and $1.3 million for Q1 2025.